Stephen Salloway

Development of Appropriate Use Recommendations for lecanemab

Prospects for Alzheimer’s disease monitoring and treatment in 2023

Why have anti-amyloid monoclonal antibodies performed differently in Phase III trials

TRAILBLAZER-ALZ 4: direct comparison of donanemab and aducanumab

Safety results of the Phase III gantenerumab GRADUATE I and II studies

Blood biomarkers in Alzheimer’s disease: appropriate use recommendations

Aducanumab updated monitoring recommendations for amyloid-related imaging abnormalities (ARIA)

Updates in pharmacological treatment of Alzheimer’s disease: lecanemab, donanemab and gantenerumab

The potential of plasma biomarkers in dementia

Donanemab: breakthrough therapy designation based on TRAILBLAZER data

Aducanumab: what’s the latest?

Major ongoing clinical trials in AD: aducanumab, donanemab & lecanemab